POM-V Prescription Required Companion Animal

MiPet Benazapet 5 mg Tablets for Cats and Dogs

Active ingredient: Benazepril Hydrochloride

Form

Tablet

Species

Cats Dogs

Manufacturer

Elanco Europe Ltd

VMD MA No.

00879/5096

What it's used for

Dogs: Treatment of congestive heart failure. Cats: Reduction of proteinuria associated with chronic kidney disease.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Benazepril Hydrochloride

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

MiPet Benazapet 5 mg Tablets for Cats and Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Dogs:
Treatment of congestive heart failure.
Cats:
Reduction of proteinuria associated with chronic kidney disease.

MiPet Benazapet tablets should be given orally once daily, with or without food.
The duration of treatment is unlimited.
MiPet Benazapet 5 mg tablets are flavoured and are taken voluntarily by most
dogs and cats.
Dogs:
MiPet Benazapet should be administered orally at a minimum dose of 0.25mg
(range 0.25-0.5) benazepril hydrochloride/kg body weight once daily, according
to the following table:
MiPet Benazapet 5 mg tabletsWeight of dog
(kg)
Standard doseDouble dose>5 - 100.5 tablet1 tablet>10 - 201 tablet2 tablets
The dose may be doubled, still administered once daily to a minimum dose of
0.5mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the
veterinary surgeon.
Cats:
MiPet Benazapet should be administered orally at a minimum dose of 0.5 mg
(range 0.5-1.0) benazepril hydrochloride/kg body weight once daily according
to the following table:
Weight of cat
(kg)
MiPet Benazapet 5 mg tablets2.5 – 50.5 tablet>5 - 101 tablet

Do not use in cases of cardiac output failure due to aortic or pulmonary
stenosis.
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.

Revised: December 2025
MA split from NI Expiry following AN: 02090/2025
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute
renal failure.
Do not use in pregnancy or lactation (section 4.7).

In double-blind clinical trials in dogs with congestive heart failure, MiPet
Benazapet was well tolerated with an incidence of adverse reactions lower than
observed in placebo-treated dogs. A small number of dogs may exhibit
transient vomiting, incoordination or signs of fatigue. On rare occasions
diarrhoea and anorexia have been reported in dogs.
In cats and dogs with chronic kidney disease, MiPet Benazapet may increase
plasma creatinine concentrations at the start of therapy. A moderate increase
in plasma creatinine concentrations following administration of ACE inhibitors
is compatible with the reduction in glomerular hypertension induced by these

Revised: December 2025
MA split from NI Expiry following AN: 02090/2025
agents, and is therefore not necessarily a reason to stop therapy in the absence
of other signs.
MiPet Benazapet may increase food consumption and body weight in cats.
Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in
rare occasions in cats.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse
reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated
reports).

None.

i. Special precautions for use in animals
The efficacy and safety of MiPet Benazapet has not been established in dogs
and cats below 2.5 kg body weight.
No evidence of renal toxicity of the veterinary medicinal product has been
observed (in dogs or cats) during clinical trials, however as is routine in cases
of chronic kidney disease, it is recommended to monitor plasma creatinine,
urea and erythrocyte counts during therapy.
ii. Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Wash hands after use.
In case of accidental oral ingestion, seek medical advice immediately and
show the label or the package leaflet to the physician.
Pregnant women should take special care to avoid accidental oral exposure
because angiotensin converting enzyme (ACE) inhibitors have been found to
affect the unborn child during pregnancy in humans.

In dogs with congestive heart failure, MiPet Benazapet tablets have been given
in combination with digoxin, diuretics, pimobendan and anti-arrhythmic
veterinary medicinal products without demonstrable adverse interactions. In
humans, the combination of ACE inhibitors and Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or
impaired renal function. The combination of MiPet Benazapet and other anti-
hypertensive agents (e.g. calcium channel blockers, or diuretics),
anaesthetics or sedatives may lead to additive hypotensive effects. Therefore,
concurrent use of NSAIDs or other medications with a hypotensive effect should
be considered with care. Renal function and signs of hypotension (lethargy,
weakness etc.) should be monitored closely and treated as necessary.

Revised: December 2025
MA split from NI Expiry following AN: 02090/2025
Interactions with potassium-preserving diuretics like spironolactone,
triamterene or amiloride cannot be ruled out. It is recommended to monitor
plasma potassium levels when using l MiPet Benazapet in combination with a
potassium-sparing diuretic because of the risk of hyperkalaemia.

Do not store above 25°C.
Return half tablet to blister pocket and store in original carton, use at next
administration.

For the full list of excipients, see section

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.